How is the Climb Bio Inc. today?

The Climb Bio Inc. today is trading in the down by -1.56% at 1.26.

How has Climb Bio Inc. performed historically?

The Climb Bio Inc. is currently trading down -1.56% on an intraday basis in the past week the index fell -9.35%. The index has been down -6.67% in the past quarter and fell -85.70% in the past year. You can view this in the overview section.

What is Climb Bio Inc. Annual Net Profit?

Climb Bio Inc. Annual Net Profit fell 110.42% in the last year to $73.9 M. Its sector's average net profit growth for the last fiscal year was -13.89%.

What is Climb Bio Inc. Price to Earning Ratio?

Climb Bio Inc. Price to Earning Ratio is -0.92, which is negative.

What is Climb Bio Inc. Stock Price?

Climb Bio Inc. Stock Price fell 85.7% and underperformed its sector by 110.51% in the past year.

What is Climb Bio Inc. Quarterly Net profit?

Climb Bio Inc. Quarterly Net profit fell 1,124.57% YoY to $20.78 M. Its sector's average net profit growth YoY for the quarter was -238.55%.

What is Climb Bio Inc. Debt to Equity Ratio?

Climb Bio Inc. Debt to Equity Ratio is zero as the company is debt-free.

What is Climb Bio Inc. Return on Equity(ROE)?

Climb Bio Inc. Return on Equity(ROE) for the last financial year was -46.26%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Climb Bio Inc. Mutual Fund Holding?

Climb Bio Inc. Mutual Fund Holding decreased by 0.09% in the last quarter to 8.49.

What is Climb Bio Inc. Institutional Holding?

Climb Bio Inc. Institutional Holding decreased by 7.33% in the last quarter to 77.32.

MARKETS
SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
INDUSTRY : BIOTECH
CLIMB BIO INC.

Climb Bio Inc. XNAS: CLYM

Climb Bio Inc. Live Share Price Today, Share Analysis and Chart

Name: Climb Bio Inc.: Is Infosys Ltd. worth buying?
Item: Climb Bio Inc.
Rating: 1.31183325
Author: Trendlyne DVM scores

about

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the pote...

1.26 -0.02 (-1.56%)

86.32% Fall from 52W High

168.4K

XNAS Volume

XNAS 13 Jun, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Climb Bio Inc. is on 26 Jun 2025 for the purpose of Eliem Therapeutics Inc Annual General Meeting for 2025 See details

Not Eligible

Expensive Valuation

14.8 / 100

Technically Neutral

37.6 / 100

No estimates available

Climb Bio Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Climb Bio Inc. Live Share Price Today, Share Analysis and Chart

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the pote...

86.32% Fall from 52W High

SWOT Analysis

Climb Bio Inc. Live Price Chart

Climb Bio Inc. FAQ

How is Climb Bio Inc. today?

Climb Bio Inc. today is trading in the red, and is down by -1.56% at 1.26.

How has Climb Bio Inc. performed historically?

Climb Bio Inc. is currently trading down -1.56% on an intraday basis. In the past week the stock fell -9.35%. stock has been down -6.67% in the past quarter and fell -85.70% in the past year. You can view this in the overview section.